NCT00473642View on ClinicalTrials.gov

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

April 30, 2010

Conditions
Age-Related MaculopathyChoroidal Neovascularization
Interventions
DRUG

Ranibizumab

intravitreal administered ranibizumab 0.5 mg in 0.05 mL

DRUG

Verteporfin

Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)

DRUG

Verteporfin

Verteporfin with standard fluence photodynamic therapy (50 J/cm2)

Trial Locations (1)

74132

Eagle Mountain Vision, Tulsa

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Oklahoma State University Center for Health Sciences

OTHER